Pancreatic tumors may require a one-two-three punch

January 15, 2018, University of Rochester Medical Center
Pancreatic tumors may require a one-two-three punch
The colors in this cell culture show action taken by pancreas cancer when it recruits harmful cells to the tumor that suppress the body’s natural immune system. Credit: University of Rochester Medical Center

One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered that a three-drug combination can simultaneously target the cancer cells as well as the other harmful, inflammatory cells within the tumor, to improve survival.

The research builds on previous scientific data from the lab of David C. Linehan, M.D., and may define a more personalized approach to treating . Ultimately, physicians will use information from the pancreas biopsy about volume and predominance of cancer and non-cancerous that impact the immune system, and then plan the best treatment.

"People with pancreatic cancer don't have 10 years to wait for the next new drug," said Linehan, a surgical oncologist, director of clinical operations at Wilmot, and the Seymour I. Schwartz Professor and Chair of the Department of Surgery at the University of Rochester Medical Center.

"Our approach is based on evidence that this disease has particular characteristics involving both the tumor and the immune response," he said, "and we believe that treatment must address all sides of the problem."

In fact, more than 80 percent of a pancreatic tumor is comprised of cells that are not malignant cancer cells. But many of these non-cancer cells, called tumor-associated macrophages (or TAMs) still play a vital role in promoting cancer by preventing the immune system from attacking the cancer. In addition to TAMs, are also comprised of and surrounded by tumor-associated neutrophils (TANs) that further block the immune system when pancreas cancer is present. (The cancer recruits these detrimental "helper" cells, TAMs and TANs, from the bone marrow.)

Patients who have a high number of TAMs and TANs in their biopsy samples have a poorer prognosis. In general, survival odds for pancreatic cancer are dismal and the incidence is rising, fueling an urgent need for improvements in treatment through research.

The objective of the study, which was published in the British medical journal Gut, was to target TAM and TAN with a combination of experimental drugs that would reduce their numbers and allow the body's own immune defenses to act appropriately and fight the cancer, and to boost the effectiveness of standard chemotherapy. The study was conducted in mice but researchers also performed correlative analyses on human pancreatic tumor samples.

Results showed that targeting TAM and TAN—as well as the —improved antitumor immunity and chemotherapy response better than using any single therapy.

The Gut journal also published an accompanying editorial by a German physician and research leader in pancreatic cancer, who said the Wilmot study provides a strong rationale for using combinations of drugs to overcome immune evasion in and other solid tumors.

Explore further: New immune-stimulating drug, with chemo, shrinks pancreas tumors

More information: Timothy M Nywening et al. Targeting both tumour-associated CXCR2+neutrophils and CCR2+macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma, Gut (2017). DOI: 10.1136/gutjnl-2017-313738

Patrick Michl et al. Overcoming immune evasion in pancreatic cancer: the combination matters, Gut (2017). DOI: 10.1136/gutjnl-2017-315443

Related Stories

New immune-stimulating drug, with chemo, shrinks pancreas tumors

April 4, 2016
The results of an early-stage (phase 1b) clinical trial for pancreatic cancer show that an experimental therapy can control tumors well enough to make some patients eligible for surgery, according to data published in The ...

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

Pancreatic cancer development

September 1, 2017
Pancreatic ductal carcinoma (PDAC) is one of the most lethal types of cancer, with new therapeutic options needed.

Promising new strategy to halt pancreatic cancer metastasis

March 2, 2015
Pancreatic cancer and its metastases might have their days numbered, according to a study published in The Journal of Experimental Medicine.

Starving pancreatic cancer cells: Scientists identify potential pancreatic cancer target

October 17, 2016
Researchers have found that a protein called SLC6A14 is overexpressed by several fold in pancreatic tumors taken from patients and in cancerous pancreatic cells lines compared with normal pancreatic tissue or normal pancreatic ...

Partnering cells turn off immune attack on pancreatic tumors

July 18, 2017
Two cell types work together to protect pancreatic tumors from destruction by the immune system. But, blocking this partnership may restore the system's ability to attack these same tumor cells.

Recommended for you

From the ashes of a failed pain drug, a new therapeutic path emerges

November 16, 2018
In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, Ph.D., and chemist Kai Johnsson, Ph.D., his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief. ...

Traditional chemotherapy superior to new alternative for oropharyngeal cancers

November 16, 2018
A drug increasingly used in combination with radiotherapy to treat a type of cancer that forms in the tonsils or the base of the tongue is inferior to a previously favored option, according to a large, clinical trial led ...

Repurposing FDA-approved drugs can help fight back breast cancer

November 16, 2018
Screening Food and Drug Administration (FDA)-approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in ...

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Standard chemotherapy treatment for HPV-positive throat cancer remains the most effective, study finds

November 15, 2018
A new study funded by Cancer Research UK and led by the University of Birmingham has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.